Abstracts tagged "large vessel vasculitis"

Abstract Number: 1868 • ACR Convergence 2021
Neutrophil Extracellular Trap Formation in Patients with Vasculitis
Despina Michailidou¹, Runa Kuley¹, Tomas Mustelin², David Cuthbertson³, Peter Grayson⁴, Nader Khalidi⁵, CURRY LEE MD KOENING⁶, Carol Langford⁷, Carol McAlear⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Antoine Sreih⁸, Kenneth Warrington¹³, Paul Monach¹⁴, Peter Merkel¹⁵ and Christian Lood², ¹Division of Rheumatology, University of Washington, Seattle, WA, ²University of Washington, Seattle, WA, ³Health Informatics Institute, University of South Florida, South Florida, FL, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁵McMaster University, Hamilton, ON, Canada, ⁶LIMITED TO OFFICIAL UNIVERSITY DUTIES ONLY, Salt Lake City, UT, ⁷Cleveland Clinic, Moreland Hills, OH, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN, ¹³Mayo Clinic, Rochester, Minnesota, ¹⁴Brigham and Women's Hospital, Boston, MA, ¹⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Neutrophil extracellular trap (NET) formation, the extrusion of chromatin and granular components from activated neutrophils, is essential in host defense. However, NET formation has…
Abstract Number: 1419 • ACR Convergence 2021
Development and Validation of a Patient Reported Outcome Measure for Giant Cell Arteritis
Mwidimi Ndosi¹, Celia Almeida², Jill Dawson³, Emma Dures², Rosemary Greenwood⁴, Catherine Guly⁵, Sarah Mackie⁶, Alison Bromhead⁴, Steve Stern⁴ and Joanna Robson², ¹University of the West of England, Bristol, Filton, United Kingdom, ²UWE Bristol, Bristol, United Kingdom, ³University of Oxford, Oxford, ⁴University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom, ⁵University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, ⁶School of Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Giant cell arteritis (GCA) causes inflammation of the blood vessels of the head and neck and can cause visual loss and large vessel vasculitis.…
Abstract Number: 013 • 2020 Pediatric Rheumatology Symposium
A Preliminary Data-driven Anatomic Classification for Childhood Takayasu Arteritis (cTA)
Ellen Go¹, Simon Eng ², David Cabral ³ and Rae Yeung ¹, ¹The Hospital for Sick Children, Toronto, Canada, ²Toronto, Canada, ³BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada
Background/Purpose: The pattern of arterial involvement and disease severity varies in those affected with cTA. Distinct imaging patterns that have some congruence with clinical phenotype…
Abstract Number: 106 • 2020 Pediatric Rheumatology Symposium
Childhood-onset Takayasu Arteritis: A Single Center Case Series of Atypical and Varied Presentations
Uptej Khalsa¹ and Imelda Balboni ¹, ¹Stanford University, Palo Alto, California
Background/Purpose: Childhood-onset Takayasu arteritis is a rare inflammatory vessel disease that predominantly affects the aorta and its major branches. Clinical presentation at disease onset can…
Abstract Number: 767 • 2019 ACR/ARP Annual Meeting
Outcome Measures in Large-Vessel Vasculitis: Relationships Between Patient, Physician, Imaging, and Laboratory-Based Domains
Casey A. Rimland¹, Kaitlin Quinn ², Joel S. Rosenblum ³, Mollie Schwartz ⁴, K Bates Gribbons ⁵, Elaine Novakovich ⁶, Antoine Sreih ⁷, Peter Merkel ⁷, Mark A. Ahlman ⁸ and Peter C. Grayson ⁹, ¹National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, Chapel Hill, NC, ²Georgetown University Hospital/National Institutes of Health, Washington, DC, ³National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, Bethesda, MD, ⁴University of Maryland, Baltimore, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶National Institutes of Health, Bethesda, MD, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by inflammation of the aorta and its major branches. The most common forms of LVV include giant cell arteritis…
Abstract Number: 798 • 2019 ACR/ARP Annual Meeting
Development of Large Vessel Vasculitis Including Aortitis in a Patient with Deficiency of the IL-1 Receptor Antagonist (DIRA) Points to Converging Roles of IL-1 and TNF in Vascular Pathogenesis Recapitulating Findings from a Murine Model
Gina Montealegre Sanchez¹, Adriana de Jesus ¹, Jenna Wade ², Katherine Townsend ¹, Arianne Soldatos ³, Alessandra Brofferio ⁴, Peter C. Grayson ⁵, Ginger Janow ⁶ and Raphaela Goldbach-Mansky ¹, ¹Translational Autoinflammatory Disease Section/NIAID/NIH, Bethesda, ²Translational Autoinflammatory Diseases Section/NIAID/NIH, Bethesda, ³NIH/NINDS, Bethesda, ⁴NIH/NHLBI, Bethesda, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁶Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, NJ
Background/Purpose: Deficiency of interleukin-1-receptor antagonist (DIRA) is a rare autoinflammatory disease caused by autosomal recessive loss of function mutations in IL1RN and characterized by early-onset generalized pustulosis,…
Abstract Number: 1210 • 2019 ACR/ARP Annual Meeting
Utilization of a Multispecialty Team for the Diagnosis of Giant Cell Arteritis Reduces Patient Morbidity
Arash Hassantoufighi ¹, Rachel Lu-Do¹, Mamta Sherchan ¹, Christopher Collins ¹, Joshpaul Dhillon ² and Florina Constantinescu ¹, ¹MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ²MedStar Washington Hospital Center, Department of Internal Medicine, Washington, DC
Background/Purpose: Giant Cell Arteritis (GCA) is an autoimmune vasculitis, most common in older adults with a peak incidence in the seventh decade. The diagnosis is…
Abstract Number: 1964 • 2019 ACR/ARP Annual Meeting
A Role for Microbiota in the Pathophysiology of Takayasu Arteritis (TAK) and Giant Cell Arteritis (GCA)
Anne Desbois¹, Dragos Ciocan ², David Saadoun ¹, Gabriel Perlemuter ³ and Patrice Cacoub ⁴, ¹GHPS, Paris, France, ²Hôpital Antoine Beclere, Clamart, France, ³Hôpital Clamart, Paris, France, ⁴AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France
Background/Purpose: The pathogenesis of Large Vessel Vasculitis (LVV) is not well understood. There is increasing evidence of a close link between intestinal dysbiosis and systemic…
Abstract Number: 2644 • 2019 ACR/ARP Annual Meeting
Ultrasound to Monitor Treatment Response in Large Vessel Giant Cell Arteritis
Anne Bull Haaversen¹, Viktoria Holt ², Shagaye Nabizadeh ², Annicken Slagsvold ² and Andreas P Diamantopoulos ³, ¹Martina Hansens Hospital, Sandvika, Norway, ²Martina Hansens Hospital, Bærum, Norway, ³Martina Hansens Hospital, SANDVIKA, Oslo, Norway
Background/Purpose: On ultrasound (US) examinations, large vessel vasculitis (LVV) has been reported to be present in up to 55% of Giant cell arteritis (GCA) patients.…
Abstract Number: 2646 • 2019 ACR/ARP Annual Meeting
Survival of Large Vessel Giant Cell Arteritis in Northern Italy During a 26-year Period : No Correlation with Demographical, Clinical, Laboratory and Imaging Data
Luigi Boiardi¹, Mariagrazia Catanoso ², Giovanna Restuccia ³, Francesco Muratore ³, Pierluigi Macchioni ⁴ and Carlo Salvarani ⁵, ¹Division of Rheumatology, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, ITALY, Reggio Emilia, Italy, ³Division of Rheumatology, Azienda Unita’ Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ⁵Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
Background/Purpose: To investigate the relationship between demographical, clinical, laboratory and imaging data and survival in patients with large vessel giant cell arteritis (LVGCA) in a…
Abstract Number: 2664 • 2019 ACR/ARP Annual Meeting
Color Doppler Ultrasound for the Diagnosis of Giant Cell Arteritis in Montreal: A Canadian Single Center Experience
Jean-Paul Makhzoum¹, Meriem Belhocine ¹, Michelle Goulet ¹, Maxime Rheaume ¹, Tara Starnino ², Stephanie Ducharme-Benard ², Guillaume Febrer ³, Yves Troyanov ⁴, Nathalie Routhier ⁵, Rosalie-Selene Meunier ⁵, Isabelle Chagnon ⁵, Michel Laurier ⁵, Maggy Helou ⁵, Nathalie Morency ⁶ and Anne-Marie Mansour ¹, ¹Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, Canada, ³Vascular Surgery, Department of Surgery, Hopital du Sacre-Coeur de Montreal, Montreal, Canada, ⁴Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁵Internal Medicine, Department of Medicine, Hopital du Sacre-Coeur de Montreal, Montreal, Canada, ⁶Division of Rheumatology, Department of Medicine, Montreal, Canada
Background/Purpose: Giant Cell Arteritis (GCA) remains challenging to diagnose as false negative temporal artery biopsy (TAB) can occur. Color doppler ultrasonography (CDUS) of the temporal,…
Abstract Number: 2673 • 2019 ACR/ARP Annual Meeting
Presentation and Management of Giant Cell Arteritis in a Real-World Setting (Artemis Study)
Alfred Mahr¹, Eric Hachulla ², Hubert de BOYSSON ³, Nassim Guerroui ⁴, Emmanuel Héron ⁵, Stéphane Vinzio ⁶, Jonathan Broner ⁷, François-Xavier Lapebie ⁸, Martin Michaud ⁹, Laurent Sailler ⁸, Thierry Zenone ¹⁰, Mohamed Djerad ¹¹, Mathieu Jouvray ¹², Emilie Shipley ¹³, Nathalie Tieulie ¹⁴, Isabelle Idier ¹⁵, Marc Paccalin ¹⁶ and Valérie Devauchelle Pensec ¹⁷, ¹Hospital Saint-Louis, University Paris Diderot, Paris, France, ²Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, ³University Hospital of Caen, Caen, France, ⁴European Hospital of Marseille, Marseille, France, ⁵Quinze-Vingt Hospital, Paris, France, ⁶GHM Grenoble, Grenoble, France, ⁷University Hospital of Nîmes, Nîmes, France, ⁸University Hospital of Toulouse, Toulouse, France, ⁹Joseph Ducuing Hospital, Toulouse, France, ¹⁰Hospital of Valence, Valence, France, ¹¹Hospital of Nevers, Nevers, France, ¹²Hospital of Arras, Arras, France, ¹³Hospital of Dax, Dax, France, ¹⁴University Hospital of Nice, Nice, France, ¹⁵Chugai Pharma France, Paris La Défense, France, ¹⁶University Hospital of Poitiers, Poitiers, France, ¹⁷University Hospital of Brest, Brest, France
Background/Purpose: We have few real-world data on the natural history and care of patients with giant cell arteritis (GCA). The objective of this observational study…
Abstract Number: 2690 • 2019 ACR/ARP Annual Meeting
Fast Track Clinic (FTC) for Giant Cell Arteritis (GCA) – the United States Experience
Ingeborg Sacksen ¹, Elizabeth Jernberg ¹, Scott Pollock ², Jean Liew ³, Sarah Chung ², R Eugene Zierler ³ and Alison Bays², ¹University of Washington Division of Rheumatology, Seattle, ²University of Washington Division of Rheumatology, Seattle, WA, ³University of Washington, Seattle, WA
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in adults and if untreated, may result in visual impairment. Although the gold…
Abstract Number: 2692 • 2019 ACR/ARP Annual Meeting
Coronary Artery Disease in a Population-Based Cohort of Biopsy-Proven Giant Cell Arteritis in Southern Sweden
Pavlos Stamatis¹, Moman Mohammad ¹, Peter Merkel ², Martin Englund ³, Carl Turesson ⁴, David Erlinge ¹ and Aladdin Mohammad ¹, ¹Lund University, Lund, Skane Lan, Sweden, ²University of Pennsylvania, Philadelphia, PA, ³Lund University, Lund, Sweden, ⁴Lund University, Malmö, Sweden
Background/Purpose: The aim of this study was to estimate the incidence rate and prevalence of coronary artery diseases (CAD) in patients with temporal artery positive…
Abstract Number: 2919 • 2019 ACR/ARP Annual Meeting
Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis
Tomoyuki Mutoh¹, Tsuyoshi Shirai ¹, Tomonori Ishii ², Yuko Shirota ³, Hideo Harigae ¹ and Hiroshi Fujii ¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Tohoku University Hospital, Sendai, Japan, ³Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan
Background/Purpose: Takayasu arteritis (TAK) is a chronic vasculitis which predominantly affects large vessels. Although anti-endothelial cell antibodies (AECA) had been reported to be involved in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].